New Zealand Formulary
Fewer cancers.
Better survival.
Equity for all.
+Apply search filters
Filters (click item to remove)
Select Filter
Cancer type
Treatment setting
Subtype
Select option
Breast
Central Nervous System
Colorectal
Desmoid fibromatosis
Giant Cell tumour of bone
Gynaecological
Head and Neck
Leukaemias
Lymphoma
Myelodysplastic syndrome
Myeloproliferative neoplasm
Neuroendocrine carcinoma
Neuroendocrine neoplasm
Neuroendocrine tumour
Plasma cell neoplasm
Respiratory
Sarcoma
Skin Cancer
Upper gastrointestinal
Urogenital
Select Setting
Adjuvant
Advanced
Definitive
Extensive
Limited
Locally advanced
Metastatic
Neoadjuvant
NON-Metastatic
Recurrent
Refractory
Relapsed
Select Subtype
Acute lymphoblastic
Acute Lymphoblastic B-cell leukaemia/lymphoma
Acute Lymphoblastic T-cell leukaemia/lymphoma
Acute myeloid
Acute promyelocytic with PML-RARA
Anal
Basal Cell
Biliary
Bladder
Bladder Urothelial
Cervical
Chronic lymphocytic
Chronic myeloid
Chronic myelomonocytic
Endometrial
Gallbladder
Gastric
Gastrointestinal stromal cell tumours
Gestational trophoblastic disease
Glioblastoma
Glioma
Hairy cell
Hepatic
Hodgkin
Mantle cell lymphoma
Melanoma
Merkel Cell
Mesothelioma
Multiple myeloma
Myelodysplastic disorders
Myelodysplastic syndrome unclassifiable
Myelofibrosis
Nasopharyngeal
Neuroendocrine
Neuroendocrine
Non small cell lung cancer
non-Hodgkin
Non-Hodgkin B-Cell
Non-Hodgkin T-cell
Oesophageal
Ovarian
Pancreas
Penile
Primary CNS lymphoma
Prostate
Rectal
Renal cell
Salivary gland
Small cell lung cancer
Soft tissue sarcoma
Squamous Cell
T-cell prolymphocytic
Testicular germ cell
Thyroid
Upper Tract Urothelial
Urothelial
Vulval
Cancer Type
—
Breast
Central Nervous System
Colorectal
Gynaecological
Head and Neck
Leukaemias
Lymphoma
Neuroendocrine
Plasma cell neoplasms
Respiratory
Sarcoma
Skin Cancer
Upper gastrointestinal
Urogenital
Request a new regimen
Terms of Use, Guidance and Disclaimers
What's new
Subscribe to monthly updates
Resources
Systemic Anti-Cancer Therapy Regimen Library
Request a new regimen
Applicant name
Applicant organisation
Applicant email
Regimen name
Indications and intent
What is the potential impact of adding this Regimen to the SACT library? (tick all that apply)
Equity - significant inequities can be addressed
Clinical outcome gains - improvement in progression free survival or overall survival
Toxicity gains - reduction in clinically significant toxicity
It will impact a large number of patients
There are major cost savings
What evidence supports the addition of this regimen? (tick all that apply)
All medications are Pharmac funded
All medications are used for Medsafe approved indications
New published RCT phase 3, (score of 4 or 5 on ESMO MCBS)
Unpublished RCT phase 3 conducted by academic group/institute (score of 4 or 5 on ESMO MCBS)
New published RCT phase 3, (score of 3 on ESMO MCBS)
Unpublished RCT phase 3 conducted by commercial sponsor (score of 4 or 5 on ESMO MCBS)
Further evidence
References
Drug and Dose Information
Drug name
Dose
Units
Route
Frequency per day
Days of each cycle
Cycle duration (days)
Add another drug
Number of cycles
Additional cycle/frequency information
Is this regimen required urgently?